AGEN_OUT_1 [2025-04-28 14:34:10 -0400] 6068 Bytes | 1763 tokens | Cum: 1763 tkns (22.04% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Agenus (AGEN) which is at $3.14 up from $2.70. So, I pulled together a bunch of data for you to look over real fast. It's still early, 2:34 PM on Mon Apr 28, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Agenus (AGEN)
IPO: 2000-02-04 (25 Years Ago)
Market Cap: $45,049,737
Shares Outstanding: 25,310,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Here’s a list of headlines for Agenus:

Apr-25-25 01:05PM - Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Apr-23-25 12:05PM - Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
Apr-23-25 12:05PM 09:40AM - Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Apr-10-25 08:52AM - Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Mar-25-25 04:40PM - Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Mar-25-25 04:40PM 09:55AM - Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Mar-19-25 07:30AM - Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Mar-12-25 03:03AM - Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges
Mar-12-25 03:03AM 01:35AM - Q4 2024 Agenus Inc Earnings Call
Mar-11-25 11:45AM - Agenus (AGEN) Q4 2024 Earnings Call Transcript
Mar-11-25 11:45AM 08:40AM - Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Mar-11-25 11:45AM 07:43AM - Agenus: Q4 Earnings Snapshot
Mar-11-25 11:45AM 07:30AM - Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
Feb-26-25 04:48PM - Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Feb-25-25 02:30PM - Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Feb-25-25 02:30PM 08:26AM - Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Feb-24-25 08:33AM - Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
Feb-23-25 07:38PM - CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Feb-21-25 09:40AM - Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Feb-06-25 08:50AM - Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum
Feb-05-25 09:40AM - Are Medical Stocks Lagging Agenus (AGEN) This Year?
Jan-29-25 12:37PM - Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Prior AI Reports for AGEN:
1. 2025-04-17 – Score: 35 – Target: 2.1000 – Highs: 2.1192 / 2.5291 / 3.30
agenus-faces-financial-challenges-amidst-speculative-trading

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-12T18:00:00Z - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
B2 - 2025-01-23T19:13:00Z - MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
B3 - 2024-11-12T17:15:14Z - Agenus (AGEN) Q3 2024 Earnings Call Transcript
B4 - 2024-11-02T11:45:00Z - DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today
B5 - 2024-10-31T09:45:00Z - Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN
B6 - 2024-10-30T22:54:00Z - Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Agenus (AGEN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

AGEN_OUT_3 [2025-04-28 14:34:10 -0400] 894 Bytes | 287 tokens | Cum: 2052 tkns (25.65% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T17:18:06Z - Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 By Investing.com...
A2 - 2025-04-25T17:19:40Z - Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025...
A3 - 2025-04-25T17:11:24Z - Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025...
A4 - 2025-04-25T12:15:06Z - B. Riley Estimates Agenus' FY2029 Earnings (NASDAQ:AGEN)...
A5 - 2025-04-23T16:04:54Z - Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AGEN_OUT_5 [2025-04-28 14:34:11 -0400] 1181 Bytes | 322 tokens | Cum: 2376 tkns (29.70% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 By Investing.com**Date: 2025-04-25Source: {'uri': 'in.investing.com', 'dataType': 'news', 'title': 'Investing.com India'}URL: https://in.investing.com/news/press-releases/agenus-botbal-data-in-pretreated-liver-cancer-presented-at-aacr-2025-93CH-4792923Durable responses observed in heavily pretreated HCC patients who progressed on approved immunotherapies

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised patients with difficult-to-treat d

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_7 [2025-04-28 14:34:12 -0400] 1181 Bytes | 260 tokens | Cum: 2638 tkns (32.98% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): isease who had progressed following standard treatments, including approved immunotherapies.

The treatment of patients with advanced HCC who progressed on immune checkpoint inhibitor therapy in first line is an area of unmet need. There is limited prospective data in this setting, mostly evaluating tyrosine kinase inhibitors. In this cohort, botensilimab and balstilimab resulted in durable responses and a clinically meaningful disease control rate in heavily pretreated HCC patients, including those who had progressed on atezolizumab/bevacizumab, said Anthony El-Khoueiry, MD, Associate Director for Clinical Research and Chief of Section of Developmental Therapeutics at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC. The preliminary activity seen in this cohort and the prospective nature of the data highlight the potential of this combination in patients with HCC

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_9 [2025-04-28 14:34:13 -0400] 1181 Bytes | 276 tokens | Cum: 2916 tkns (36.45% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): , including those who have progressed on other immunotherapies. Further evaluation is warranted.

Phase 1 Study Overview: BOT/BAL in Treatment-Refractory Hepatocellular Carcinoma (NCT03860272)

The HCC cohort enrolled 19 patients (18 evaluable for efficacy) with treatment-refractory metastatic HCC. Patients received a median of two prior therapies, and progressed on or following anti-PD(L)-1. Patients were administered BOT (1 or 2 mg/kg) in combination with BAL (3 mg/kg).

The safety profile of the BOT/BAL combination remained consistent with previous cohorts and was manageable.

These results further support the potential of botensilimab and balstilimab to provide durable responses across multiple advanced, treatment-refractory cancers, said Steven O'Day, MD, Chief Medical Officer at Agenus. The consistency of these responses across various challenging tumor types underscores the potent

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_11 [2025-04-28 14:34:14 -0400] 1181 Bytes | 278 tokens | Cum: 3196 tkns (39.95% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): ial clinical utility of this combination therapy.

The presentation will be available on Agenus' website at https://agenusbio.com/publications/ following the conference session.

About Botensilimab (BOT)

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to cold tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_13 [2025-04-28 14:34:15 -0400] 1181 Bytes | 290 tokens | Cum: 3488 tkns (43.60% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): clinical responses across nine metastatic, late-line cancers. Approximately 1,100 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit www.clinicaltrials.gov.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_15 [2025-04-28 14:34:16 -0400] 1181 Bytes | 261 tokens | Cum: 3751 tkns (46.89% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): , using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

-- disclaimer trimmed -- These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Q

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_17 [2025-04-28 14:34:17 -0400] 868 Bytes | 198 tokens | Cum: 3951 tkns (49.39% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): uarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250425819815/en/

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_19 [2025-04-28 14:34:18 -0400] 798 Bytes | 202 tokens | Cum: 4155 tkns (51.94% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S9 - 2025-03-17 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Overview

Agenus Inc. (including its subsidiaries, collectively referred to as Agenus, the Company, we, us, and our) is a clinical-stage biotechnology company specializing in discover...

S10 - 2025-03-17 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Overview

Agenus Inc. (including its subsidiaries, collectively referred to as Agenus, the Company, we, us, and our) is a clinical-stage biotechnology company specializing in discove...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AGEN_OUT_21 [2025-04-28 14:34:18 -0400] 1181 Bytes | 274 tokens | Cum: 4431 tkns (55.39% of 8k)
==========================================================================

Showing S9 (chunk 1 of 6): S9:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

Overview

Agenus Inc. (including its subsidiaries, collectively referred to as Agenus, the Company, we, us, and our) is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. Our pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc. ("MiNK")), and vaccine adjuvants (via SaponiQx, Inc. ("SaponiQx")). Our primary focus is immuno-oncology (I-O), and our diverse pipeline is supported by our in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. To succeed in I-O, innovation and speed are paramount. We are a vertically integrated biotechnology company equipped with a suite of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_23 [2025-04-28 14:34:19 -0400] 1181 Bytes | 234 tokens | Cum: 4667 tkns (58.34% of 8k)
==========================================================================

Showing S9 (chunk 2 of 6): technology platforms to advance from novel target identification through manufacturing for clinical trials of antibodies and cell therapies. By understanding each patient's cancer, we aim to substantially expand the population benefiting from current I-O therapies. In addition to a diverse pipeline, we have assembled fully integrated end-to-end capabilities including novel target discovery, antibody generation, cell line development and cGMP manufacturing. Leveraging our science and capabilities, we have established strategic partnerships to advance innovation. We believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined with novel immunomodulatory agents designed to address underlying tumor escape mechanisms.

Our I-O portfolio is driven by several platforms and programs, which we plan to utilize individually and i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_25 [2025-04-28 14:34:21 -0400] 1181 Bytes | 289 tokens | Cum: 4958 tkns (61.98% of 8k)
==========================================================================

Showing S9 (chunk 3 of 6): n combination:

Multiple antibody discovery platforms, including proprietary display technologies, to identify future antibody candidates.

Antibody candidate programs, including our lead assets, botensilimab ("BOT") (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, also known as AGEN1181) and balstilimab ("BAL") (a programmed death receptor-1 (PD-1) blocking antibody).

Our saponin-based vaccine adjuvant platform, primarily centered around our STIMULON cultured plant cell (cpc) QS-21 adjuvant (STIMULON cpcQS-21).

A pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK.

We regularly evaluate development, commercialization, and partnering strategies for each product candidate based on various factors, includ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_27 [2025-04-28 14:34:21 -0400] 1181 Bytes | 268 tokens | Cum: 5228 tkns (65.35% of 8k)
==========================================================================

Showing S9 (chunk 4 of 6): ing pre-clinical and clinical trial results, competitive positioning, funding requirements, and available resources. Our lead program, BOT is progressing through multiple clinical programs as a monotherapy and in combination with BAL. In April 2023, BOT in combination with BAL received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with non-microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer without active liver involvement. This designation specifically targets patients who are heavily pretreated and have shown resistance or intolerance to standard chemotherapies, including fluoropyrimidine, oxaliplatin, and irinotecan, as well as those who have received a VEGF inhibitor, an EGFR inhibitor, and/or a BRAF inhibitor, if indicated. Based on the BOT/BAL clinical data generated to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_29 [2025-04-28 14:34:22 -0400] 1181 Bytes | 290 tokens | Cum: 5520 tkns (69.00% of 8k)
==========================================================================

Showing S9 (chunk 5 of 6): date, we have developed designs for registration-enabling trials in MSS CRC across neoadjuvant, first-line, and late-line mCRC. These trial(s) will launch upon completion of strategic transactions. The options being considered are partnerships, licensing, or joint ventures.

We have entered into collaborations with several companies, including Bristol-Myers Squibb Company (BMS), Betta Pharmaceuticals Co., Ltd. (Betta), UroGen Pharma Ltd. (UroGen), Gilead Sciences, Inc. (Gilead), Incyte Corporation (Incyte), and Merck Sharp Dohme (Merck). These collaborations, along with our internal programs, have resulted in over a dozen antibody pre-clinical or clinical development programs.

Pursuant to our collaboration agreement with Incyte, we had exclusively licensed to Incyte monospecific antibodies targeting GITR, OX40, TIM-3 and LAG-3, as well as an additional undisclosed target. Under the te

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_31 [2025-04-28 14:34:23 -0400] 790 Bytes | 194 tokens | Cum: 5716 tkns (71.45% of 8k)
==========================================================================

Showing S9 (chunk 6 of 6): rms of our agreement, Incyte was responsible for all future development expenses, and we were eligible to receive up to an additional $315.0 million in potential milestone payments plus royalties on any future sales. Incyte has terminated the OX40 program, effective October 2023, and both the GITR program and undisclosed program, effective May 2024. Upon termination, the rights to the OX40, GITR, and undisclosed programs reverted back to us. In July 2024, Incyte announced that it would discontinue f...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AGEN_OUT_33 [2025-04-28 14:34:28 -0400] 6966 Bytes | 1958 tokens | Cum: 7676 tkns (95.95% of 8k)
==========================================================================

This is our set of metrics for Agenus.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 985,162 | Perf Month: 87.05% | Option/Short: Yes / Yes | Sales Y/Y TTM: -33.81% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 529.31K | Perf Quarter: -13.75% | Short Float: 16.77% | ROE: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 2.47 | Index: RUT | Short Ratio: 7.81 | ROI: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 72.97 | Market Cap: 78.58M | Short Interest: 4.13M | Sales Surprise: -11.35% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.31 | Shs Outstand: 25.31M | Beta: 1.44 | EPS Surprise: 19.75% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 53.96% | Shs Float: 24.64M | Sales Q/Q: -67.98% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: 39.49% | Inst Own: 32.04% | Sales past 5Y: 30.58% | Earnings: Mar 11 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -24.31% | Insider Own: 2.64% | Employees: 316 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 34.42% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Agenus officers or majority shareholders (if available).

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-04-18
- Common Stock: 7886 shares at $2.08 (D)

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-04-04
- Common Stock: 1159 shares at $1.56 (D)

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-04-04
- Common Stock: 10288 shares at $1.56 (D)

Inside Trans: AGENUS INC (AGEN) by HARRISON THOMAS L (Unknown Title) on 2025-04-01
- Common Stock: 8898 shares at $2.88 (D)

Inside Trans: AGENUS INC (AGEN) by Wright Timothy (Unknown Title) on 2025-04-01
- Deferred Stock Units: 3255.585 shares at $N/A (D)

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-03-21
- Common Stock: 1123 shares at $1.61 (D)

Inside Trans: AGENUS INC (AGEN) by ARMEN GARO H (See Remarks) on 2025-03-21
- Common Stock: 9243 shares at $1.61 (D)

Inside Trans: AGENUS INC (AGEN) by Buell Jennifer (Unknown Title) on 2025-03-07
- Common Stock: 409 shares at $2.35 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 103463000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -232271000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.1397
Average Volume: 785553.85
30-Day High: 3.1397
30-Day Low: 1.505

[Detailed Financials: TTM 2024]
- Total Assets: $226,271,000.00
- Total Liabilities: $532,695,000.00
- Total Equity: $-306,424,000.00
- Current Assets: $45,574,000.00
- Current Liabilities: $221,401,000.00

[Income Statement: TTM 2024]
- Revenue: $103,463,000.00
- Net Income: $-232,271,000.00
- Gross Profit: $102,977,000.00
- Operating Income: $-120,475,000.00
- Earnings Per Share (EPS): -10.59

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-35,448,000.00

[Detailed Financials: FY 2024]
- Total Assets: $226,271,000.00
- Total Liabilities: $532,695,000.00
- Total Equity: $-306,424,000.00
- Current Assets: $45,574,000.00
- Current Liabilities: $221,401,000.00

[Income Statement: FY 2024]
- Revenue: $103,463,000.00
- Net Income: $-232,271,000.00
- Gross Profit: $102,977,000.00
- Operating Income: $-120,475,000.00
- Earnings Per Share (EPS): -10.59

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-35,448,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Agenus (AGEN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Agenus.

2) MARKET_SCORE[]
This conversation was initiated because AGEN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for AGEN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, AGEN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect AGEN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Agenus.

11) ETHICAL_RATING[]
Rate Agenus’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Agenus.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

AGEN_IN_35 [2025-04-28 14:34:29 -0400] 126 Bytes | 29 tokens | Cum: 7911 tkns (98.89% of 8k)
==========================================================================

====================================
[2025-04-28 14:34:29] # Analysis Completed
Elapsed Time: 20.34 seconds